USP17L2 and non-small cell lung carcinoma: Therefore, as we have shown that USP17 is required for EGFR CME [8], and mutant EGFR preferentially undergoes CME promoting its recycling and its oncogenic activity [22], we wanted to examine if the impact of USP17 depletion would be more potent in EGFRMT NSCLC cells.